SUTRO BIOPHARMA, INC.: net property, plant and equipment
Net property, plant and equipment for SUTRO BIOPHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All SUTRO BIOPHARMA, INC. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 10,648,000 | USD | 2026-03-23 | 10-K · 0001193125-26-119873 |
| At date | 2024-12-31 | 18,190,000 | USD | 2026-03-23 | 10-K · 0001193125-26-119873 |
| At date | 2023-12-31 | 21,940,000 | USD | 2025-03-13 | 10-K · 0000950170-25-038884 |
| At date | 2022-12-31 | 24,621,000 | USD | 2024-03-25 | 10-K · 0000950170-24-035949 |
| At date | 2021-12-31 | 22,550,000 | USD | 2023-03-30 | 10-K · 0000950170-23-010976 |
| At date | 2020-12-31 | 12,935,000 | USD | 2022-02-28 | 10-K · 0000950170-22-002312 |
| At date | 2019-12-31 | 9,633,000 | USD | 2021-03-18 | 10-K · 0001564590-21-013945 |
| At date | 2018-12-31 | 10,934,000 | USD | 2020-03-16 | 10-K · 0001564590-20-010890 |
| At date | 2017-12-31 | 13,997,000 | USD | 2019-04-01 | 10-K · 0001564590-19-010253 |
Related financial histories
- SUTRO BIOPHARMA, INC.: total assets
- SUTRO BIOPHARMA, INC.: total liabilities
- SUTRO BIOPHARMA, INC.: stockholders equity
- SUTRO BIOPHARMA, INC.: cash and cash equivalents
- SUTRO BIOPHARMA, INC.: net income or loss
- SUTRO BIOPHARMA, INC.: operating cash flow
- SUTRO BIOPHARMA, INC.: capital expenditure payments
- SUTRO BIOPHARMA, INC.: revenue
- SUTRO BIOPHARMA, INC.: contract revenue excluding tax
- SUTRO BIOPHARMA, INC.: financing cash flow
- SUTRO BIOPHARMA, INC.: investing cash flow
- SUTRO BIOPHARMA, INC.: retained earnings or deficit
- SUTRO BIOPHARMA, INC.: basic weighted-average shares
- SUTRO BIOPHARMA, INC.: diluted weighted-average shares
- SUTRO BIOPHARMA, INC.: basic earnings per share
- SUTRO BIOPHARMA, INC.: diluted earnings per share
- SUTRO BIOPHARMA, INC.: income tax expense or benefit
- SUTRO BIOPHARMA, INC.: share-based compensation expense
- SUTRO BIOPHARMA, INC.: operating income or loss
- SUTRO BIOPHARMA, INC.: current assets
- SUTRO BIOPHARMA, INC.: interest expense
- SUTRO BIOPHARMA, INC.: current liabilities
- SUTRO BIOPHARMA, INC.: current accounts payable
- SUTRO BIOPHARMA, INC.: net current accounts receivable
- SUTRO BIOPHARMA, INC.: operating expenses
- SUTRO BIOPHARMA, INC.: research and development expense
Inspect the source
- Entity
- SUTRO BIOPHARMA, INC. / CIK 0001382101
- Captured
- 2026-09-20T07:58:19.143Z
- SEC response SHA-256
edbbe5f19eb32d9e9b30b5efb21d584273fd4e0e4ee6ba6b9ca96185a3d014ff
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001382101.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))